NDAINTRAVENOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE (bivalirudin) by Baxter is anion-binding exosite of circulating and clot-bound thrombin. Approved for coronary artery disease, acute coronary syndrome, myocardial infarction. First approved in 2017.
Drug data last refreshed 23h ago
Mechanism of Action
anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked…
Indications (3)
Worked on BIVALIRUDIN IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.